Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team.
about
Diagnosis, assessment, and phenotyping of COPD: beyond FEV₁Biomarkers of progression of chronic obstructive pulmonary disease (COPD)Is there still hope for single therapies: how do we set up experimental systems to efficiently test combination therapies?Predictive medicine: outcomes, challenges and opportunities in the Synergy-COPD projectA review of national guidelines for management of COPD in EuropeThe association between risk of airflow limitation and serum uric acid measured at medical health check-upsPhenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE Study.Multiple biomarkers predict disease severity, progression and mortality in COPD.The science of clinical practice: disease diagnosis or patient prognosis? Evidence about "what is likely to happen" should shape clinical practice.Exhaled volatile organic compounds discriminate patients with chronic obstructive pulmonary disease from healthy subjects.Neutrophil extracellular trap (NET) formation characterises stable and exacerbated COPD and correlates with airflow limitationPredictors of Hospitalized Exacerbations and Mortality in Chronic Obstructive Pulmonary Disease.Physical inactivity and arterial stiffness in COPD.Loss of Peripheral Tolerance in Emphysema. Phenotypes, Exacerbations, and Disease Progression.Clinical and Immunological Factors in Emphysema Progression. Five-Year Prospective Longitudinal Exacerbation Study of Chronic Obstructive Pulmonary Disease (LES-COPD)COPD exacerbations by disease severity in EnglandAssisted ventilation in COPD - association between previous hospitalizations and mortality.Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management.Individualized lung function trends in alpha-1-antitrypsin deficiency: a need for patience in order to provide patient centered management?Alterations in Serum Polyunsaturated Fatty Acids and Eicosanoids in Patients with Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)Impaired Blood Neutrophil Function in the Frequent Exacerbator of Chronic Obstructive Pulmonary Disease: A Proof-of-Concept StudyEffect of Aclidinium Bromide on Exacerbations in Patients with Moderate-to-Severe COPD: A Pooled Analysis of Five Phase III, Randomized, Placebo-Controlled StudiesBiomarkers of extracellular matrix turnover are associated with emphysema and eosinophilic-bronchitis in COPD.Chronic Obstructive Pulmonary Disease heterogeneity: challenges for health risk assessment, stratification and management.Strategies for reducing the risk of cardiovascular disease in patients with chronic obstructive pulmonary disease.Efficacy of inhaled medications in asthma and COPD related to disease severity.An ECLIPSE View of Alpha-1 Antitrypsin Deficiency.Lung Mass in Smokers.Phenotyping Before Starting Treatment in COPD?Should the diagnosis of COPD be based on a single spirometry test?Relationship between FEV1 and arterial stiffness in elderly people with chronic obstructive pulmonary disease.Clinical characteristics of chronic bronchitic, emphysematous and ACOS phenotypes in COPD patients with frequent exacerbations.Role of Proteases in Chronic Obstructive Pulmonary Disease.CT Scanning in COPD - Is it Time to Move On?Serum Proteins Associated with Emphysema Progression in Severe Alpha-1 Antitrypsin DeficiencyThe COPD Pipeline XXVII.Long-term treatment with budesonide/formoterol attenuates circulating CRP levels in chronic obstructive pulmonary disease patients of group DMeta-analysis of routine blood tests as predictors of mortality in COPD.Mid-regional pro-adrenomedullin and copeptin to predict short-term prognosis of COPD exacerbations: a multicenter prospective blinded study.The value of blood cytokines and chemokines in assessing COPD.
P2860
Q26764897-5448EA82-E1A7-4E69-AE34-1D5B30F72F9BQ26996356-91207FB8-6C68-441E-B4C6-6573C6F6F41DQ26998459-2B175E9A-1727-41F7-B6C5-8FAA09B826E1Q27014689-3B9C0413-B0AD-434E-A1D8-DB9A717F2AC1Q28072014-95FA663F-45DC-4A12-BC50-23DCA5B39A99Q33596469-1B16BD51-AB22-47EF-90A1-35D983CC9F47Q33768773-492CEF10-6F68-4F78-BC53-BC1D39A8B8E3Q33796180-0964F66F-951E-4BEC-A417-456518495172Q35030034-502207E8-0601-40F5-A205-6F91339DC40FQ35136150-DEE6D4B4-6544-468E-9A09-C9D6DEEF34E4Q35637182-1ADF08DA-EA55-4670-934C-4327E6BCCCFEQ36065017-D32A1DB1-73C5-43E1-895A-05479A8CFB5DQ36068392-0A1A76E0-79BF-409B-AE35-133F5979FA34Q36490148-FB1E1C33-F35C-4D8D-AE80-50E290308D76Q36516546-315D463F-3B6E-4E70-9E0D-915A55E8D0F2Q36776335-5873B50B-7371-4C7B-93CA-BF642848D1D4Q36883259-23AB2B3B-5BF0-4CDB-A0DD-94410386339EQ36907742-0DAF7A04-2A19-470D-BE0F-C98852F202BAQ37158517-E9EA3D11-146F-47EC-901C-5ED3E69AF64AQ37286652-30B13CA1-DAC8-4371-9D85-C287ED7BB520Q37389685-9AB16C81-7D10-4921-8F8F-343733CDA630Q37494942-17652A8B-D318-4FE3-B2B7-87AD0541B074Q37595806-CF1D4329-E826-42C0-8F10-20155BA708E9Q38282787-1B76C99D-B4AF-4951-8BE2-FB7BE194414EQ38345525-21C9FD7A-6DEE-45D0-9A88-24A53AF0DF76Q38862781-18E5249A-14C0-40F8-968F-CB71583DC01CQ38937853-410DC3CB-102A-4BE3-93C8-F777518AB6D7Q39112080-409ED31E-322C-4A1F-B00E-5DD494DF687CQ39226768-7625ABED-AA46-415C-8EF7-0EA6A3041E22Q39339535-8E2CAA97-C24C-4314-955C-E1A139638300Q40840356-496282D0-14E9-47BB-9149-10FD339DD550Q41144316-1471096D-C266-422D-9232-1B69F2D78D63Q41333629-BAE392DA-7C0B-446C-9E1F-5AAE517DC42CQ41400890-F9EF5ED2-4300-42CD-AE5B-4C0567085EA2Q41401443-02B24A40-2B46-471F-AC84-7B9178BAEB02Q41402557-CCD53D39-8ACA-4503-BBDB-8E72046509B7Q41496258-3BD5176E-5B69-49B0-B29F-C3471468AC07Q42036397-55EBB87E-E5FD-4D02-9E56-ECEE4CAAA898Q42292636-2217CCF8-825E-44E8-8427-C96AC613244FQ42634551-FC44ED13-2DCF-4EB4-A826-4F33801286E0
P2860
Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Should we view chronic obstruc ...... rspective from the study team.
@en
Should we view chronic obstruc ...... rspective from the study team.
@nl
type
label
Should we view chronic obstruc ...... rspective from the study team.
@en
Should we view chronic obstruc ...... rspective from the study team.
@nl
prefLabel
Should we view chronic obstruc ...... rspective from the study team.
@en
Should we view chronic obstruc ...... rspective from the study team.
@nl
P2093
P2860
P50
P1476
Should we view chronic obstruc ...... rspective from the study team.
@en
P2093
Alvar Agusti
Bartolome Celli
Bruce Miller
Courtney Crim
David A Lomas
Edwin K Silverman
Evaluation of COPD Longitudina ...... Endpoints Study Investigators
Harvey Coxson
Julie C Yates
Lisa D Edwards
P2860
P304
P356
10.1164/RCCM.201311-2006PP
P407
P577
2014-05-01T00:00:00Z